Kawagoe K
Nihon Gan Chiryo Gakkai Shi. 1989 Apr 20;24(4):765-71.
As the treatment of inoperable, radioresistant or recurrent cases of uterine cancer (cervical or endometrial) whose lesions were restricted to the pelvis, internal iliac arterial chemotherapy was carried out and its therapeutic results were evaluated. Thirty three cases including 22 primary and 11 recurrent ones were dealt with this study. Among 33 cases, catheter was introduced to the internal iliac artery via superior gluteal artery in 9, inferior gluteal artery in 22 and lateral umbilical artery in 2 cases. Oncostatics, including mainly cisplatin, adriamycin and pepleomycin, were administered via artery daily or once or three times a week with indwelling of the catheter as long as 7 months in average. Eight patients out of 33 were living with average survival time of 18.2 months following the initiation of intra-arterial chemotherapy. Among 27 cases whose therapeutic effects were evaluable histologically, tumor cells had disappeared as long as at least 4 months in 23, within 4 months in 3 cases and tumor cells continued to be present in one case. In 22 primary cases, 3 were living without evidence of disease, one was living with disease and remaining 18 cases were dead due to other diseases in two cases, distant metastasis in 7 cases, troubles of the primary site in 8 cases and unknown reason (septic shock?) in one case. Four of 11 recurrent cases were living with one case of tumor bearing state. Complete response (CR) was obtained in 5 cases and partial response (PR) in 4 among 9 evaluable recurrent cases. As for the recurrent cases whose main therapy was intra-arterial chemotherapy only, CR was gained in 3 and PR was got in 4 out of 7 cases. Severe side effects were observed in 11, moderate one in 15 and mild one in 6 cases.
对于病变局限于盆腔的无法手术、对放疗耐药或复发的子宫癌(宫颈癌或子宫内膜癌)病例,进行了髂内动脉化疗并评估其治疗效果。本研究共处理了33例病例,其中包括22例原发性病例和11例复发病例。在这33例病例中,9例经臀上动脉将导管引入髂内动脉,22例经臀下动脉,2例经脐外侧动脉。主要包括顺铂、阿霉素和平阳霉素的抗癌药通过动脉每日给药,或每周给药一次或三次,导管留置时间平均长达7个月。33例患者中有8例存活,动脉内化疗开始后的平均生存时间为18.2个月。在27例可进行组织学疗效评估的病例中,23例肿瘤细胞至少消失了4个月,3例在4个月内消失,1例肿瘤细胞持续存在。在22例原发性病例中,3例无疾病证据存活,1例带瘤存活,其余18例中,2例因其他疾病死亡,7例远处转移,8例原发部位出现问题,1例原因不明(感染性休克?)。11例复发病例中有4例存活,其中1例为带瘤状态。在9例可评估的复发病例中,5例获得完全缓解(CR),4例获得部分缓解(PR)。对于仅以动脉内化疗作为主要治疗方法的复发病例,7例中有3例获得CR,4例获得PR。观察到11例有严重副作用,15例有中度副作用,6例有轻度副作用。